On October 3, Eli Lilly presented the latest research data on Tirzepatide at the 59th Annual meeting of the European Association for the Study of Diabetes (EASD). The results showed that Tirzepatide (10mg, 15mg) met the co-primary endpoint and all key secondary endpoints, achieving significant and clinically meaningful weight loss in Chinese adult obese and overweight patients.

SURMOUNT-CN Phase III clinical study results showed that obese and overweight Chinese adults treated with Tirzepatide experienced up to 19.9% weight loss from baseline at week 52. The proportion of participants in the Tirzepatide 15mg group who achieved weight loss of ≥5% (one of the co-primary endpoints) was 92.7%.
Lilly said the overall safety profile of Tirzepatide in the SURMOUNT-CN trial was similar to that reported in previous trials, and no new safety signals were found. The most commonly reported intratreatment adverse events in the Tirzepatide group were gastrointestinal adverse events, which were mostly mild to moderate in severity and occurred primarily during dose escalation.